drugset / Trial / NCT02544932

Pleotropic Effect of New Oral Anticoagulants

NCT02544932

Phase 3 Unknown 55 enrolled Kyunghee University Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.

Timeline

Start
2015-10
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran Unknown 110 mg Oral
Subject Dabigatran Unknown 150 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral
Comparator Warfarin Small molecule

Indications